

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the prospectus dated August 10, 2021 (the “**Prospectus**”) issued by Shanghai HeartCare Medical Technology Corporation Limited (上海心璋醫療科技股份有限公司) (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in Hong Kong, the United States or elsewhere. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”). The Offer Shares may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States. The Offer Shares may be offered, sold or delivered (i) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (ii) outside of the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.

In connection with the Global Offering, Goldman Sachs (Asia) L.L.C. as stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may over-allocate and effect transactions with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period after Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilization action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the H Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, and demand for the H Shares, and therefore the price of the H Shares, could fall.

Potential investors of the Offer Shares should note that the Joint Global Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. on the Listing Date (which is currently expected to be on Friday, August 20, 2021).

**Shanghai HeartCare Medical Technology  
Corporation Limited**  
**上海心瑋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**GLOBAL OFFERING**

**Number of Offer Shares under the Global Offering** : 6,601,850 H Shares (subject to the Over-allotment Option)  
**Number of Hong Kong Offer Shares** : 660,200 H Shares (subject to adjustment)  
**Number of International Offer Shares** : 5,941,650 H Shares (subject to adjustment and the Over-allotment Option)  
**Maximum Offer Price** : HK\$171.00 per H Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)  
**Nominal value** : RMB1.00 per H Share  
**Stock code** : 6609

*Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers*

**Goldman  
Sachs**

 **CICC**中金公司

*Joint Bookrunner and Joint Lead Manager*

 **富途證券**

## **IMPORTANT NOTICE TO INVESTORS: FULLY ELECTRONIC APPLICATION PROCESS**

**We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of the Prospectus or printed copies of any application forms to the public in relation to the Hong Kong Public Offering.**

**The Prospectus is available at the website of the Hong Kong Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) under the “*HKEXnews > New Listings > New Listing Information*” section, and our website at [www.strokemedical.com](http://www.strokemedical.com). If you require a printed copy of the Prospectus, you may download and print from the website addresses above.**

To apply for the Hong Kong Public Offer Shares, you may:

- (1) apply online through the **White Form eIPO** service at [www.eipo.com.hk](http://www.eipo.com.hk); or
- (2) apply through the **CCASS E IPO** service to electronically cause HKSCC Nominees to apply on your behalf, including by:
  - (i) instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Public Offer Shares on your behalf; or
  - (ii) (if you are an existing **CCASS Investor Participant**) giving **electronic application instructions** through the CCASS Internet System (<https://ip.ccass.com>) or through the CCASS Phone System by calling +852 2979 7888 (using the procedures in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC can also input **electronic application instructions** for CCASS Investor Participants through HKSCC’s Customer Service Centre at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong by completing an input request.

If you have any question about the application for the Hong Kong Public Offer Shares, you may call the enquiry hotline of our H Share Registrar and **White Form eIPO** Service Provider, Computershare Hong Kong Investor Services Limited, both at +852 2862 8646 on the following dates:

Tuesday, August 10, 2021 – 9:00 a.m. to 9:00 p.m.  
 Wednesday, August 11, 2021 – 9:00 a.m. to 9:00 p.m.  
 Thursday, August 12, 2021 – 9:00 a.m. to 9:00 p.m.  
 Friday, August 13, 2021 – 9:00 a.m. to 12:00 noon

We will not provide any physical channels to accept any application for the Hong Kong Public Offer Shares by the public. The contents of the electronic version of the Prospectus are identical to the printed Prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

If you are an **intermediary, broker or agent**, please remind your customers, clients or principals, as applicable, that the Prospectus is available online at the website addresses above.

Please refer to the section headed “How to Apply for Hong Kong Offer Shares” in the Prospectus for further details on the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application through the **White Form eIPO** service or by giving **electronic application instructions** to HKSCC must be for a minimum of 50 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select.

**Shanghai HeartCare Medical Technology Corporation Limited**  
**(HK\$171.00 per Hong Kong Offer Share)**

**NUMBER OF HONG KONG OFFER SHARES THAT MAY BE APPLIED FOR AND PAYMENTS**

No. of Hong Kong Offer Shares applied for	No. of Hong Kong Offer Shares applied for	No. of Hong Kong Offer Shares applied for	Amount payable on application	Amount payable on application	Amount payable on application	No. of Hong Kong Offer Shares applied for	Amount payable on application
			HK\$	HK\$	HK\$		HK\$
50	8,636.16	700	120,906.22	5,000	863,615.84	40,000	6,908,926.68
100	17,272.32	800	138,178.53	6,000	1,036,339.00	45,000	7,772,542.52
150	25,908.47	900	155,450.86	7,000	1,209,062.17	50,000	8,636,158.35
200	34,544.63	1,000	172,723.17	8,000	1,381,785.34	60,000	10,363,390.02
250	43,180.79	1,500	259,084.76	9,000	1,554,508.50	70,000	12,090,621.69
300	51,816.96	2,000	345,446.33	10,000	1,727,231.67	80,000	13,817,853.36
350	60,453.11	2,500	431,807.92	15,000	2,590,847.51	90,000	15,545,085.03
400	69,089.27	3,000	518,169.50	20,000	3,454,463.34	100,000	17,272,316.70
450	77,725.43	3,500	604,531.09	25,000	4,318,079.18	150,000	25,908,475.05
500	86,361.59	4,000	690,892.67	30,000	5,181,695.01	200,000	34,544,633.40
600	103,633.90	4,500	777,254.26	35,000	6,045,310.85	330,100 <sup>(1)</sup>	57,015,917.43

(1) Maximum number of Hong Kong Offer Shares you may apply for.

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

## THE LISTING APPLICATION

The Company has applied to the Stock Exchange for the listing of, and permission to deal in, the H Shares to be issued pursuant to the Global Offering (including any H Shares to be issued pursuant to the exercise of the Over-Allotment Option) and the H Shares to be converted from the Unlisted Foreign Shares upon completion of the Global Offering.

## STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises:

- the Hong Kong Public Offering of initially 660,200 H Shares (subject to adjustment) representing approximately 10.0% of the total number of Offer Shares initially available under the Global Offering, and
- the International Offering of initially 5,941,650 H Shares (subject to adjustment and the Over-allotment Option) representing approximately 90.0% of the total number of Offer Shares initially available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, subject to the requirements under Practice Note 18 of the Listing Rules and Guidance Letter HKEX-GL91-18, the Joint Global Coordinators may, at their sole discretion, reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the maximum total number of Offer Shares that may be allocated to the Hong Kong Public Offering following such reallocation shall not exceed 660,200 H Shares, representing approximately 10% of the Offer Shares initially available under the Global Offering, increasing the total number of Offer Shares available under the Hong Kong Public Offering to 1,320,400 H Shares, representing approximately 20% of the Offer Shares and the final Offer Price shall be fixed at the bottom end of the indicative Offer Price range (i.e. HK\$160.00 per Offer Share) stated in the Prospectus.

In connection with the Global Offering and pursuant to International Underwriting Agreement, the Company is expected to grant to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters), the Over-allotment Option, exercisable within 30 days from the last day for lodging applications under the Hong Kong Public Offering to require the Company to issue and allot up to 990,250 additional Offer Shares, representing approximately 15% of the Offer Shares initially available under the Global Offering, at the Offer Price, to cover over-allocations in the International Offering, if any. In the event the Over-allotment Option is exercised, the Company will make an announcement which will be posted on the website of the Hong Kong Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and on our website ([www.strokemedical.com](http://www.strokemedical.com)), respectively.

## PRICING

The Offer Price will not be more than HK\$171.00 per Offer Share and is currently expected to be not less than HK\$160.00 per Offer Share, unless otherwise announced as further explained in the section headed “Structure of the Global Offering” in the Prospectus. Applicants for the Hong Kong Offer Shares are required to pay, on application, the maximum Offer Price of HK\$171.00 per Offer Share together with brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK\$171.00 per Offer Share.

## EXPECTED TIMETABLE

Hong Kong Public Offering commences ..... 9:00 a.m. on  
Tuesday, August 10, 2021

Latest time to complete electronic applications  
under **White Form eIPO** service through  
the designated website [www.eipo.com.hk](http://www.eipo.com.hk) ..... 11:30 a.m. on  
Friday, August 13, 2021

Application lists of the Hong Kong Public Offering open ..... 11:45 a.m. on  
Friday, August 13, 2021

Latest time to complete payment of **White Form eIPO**  
applications by effecting Internet banking transfer(s)  
or PPS payment transfer(s) ..... 12:00 noon on  
Friday, August 13, 2021

If you are instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Public Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

Application lists of the Hong Kong Public Offering close ..... 12:00 noon on  
Friday, August 13, 2021

Expected Price Determination Date ..... Friday, August 13, 2021

(1) Announcement of Offer Price, an indication  
of the level of interest in the International Offering,  
the level of applications in the Hong Kong Public Offering  
and the basis of allocation of the Hong Kong Offer Shares  
to be published on our website at [www.strokemedical.com](http://www.strokemedical.com)  
and the websites of the Stock Exchange  
at [www.hkexnews.hk](http://www.hkexnews.hk) on or before ..... Thursday, August 19, 2021

(2) Announcement of results allocations in the Hong Kong Public Offering (including successful applicants' identification document numbers, where appropriate) to be available through a variety of channels including the websites of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and our Company's website at [www.strokemedical.com](http://www.strokemedical.com) (see "How to Apply for Hong Kong Offer Shares - 12. Publication of Results" in the Prospectus) from . . . . . Thursday, August 19, 2021

(3) A full announcement of the Hong Kong Public Offering containing (1) and (2) above to be published on the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and our Company's website at [www.strokemedical.com](http://www.strokemedical.com) from. . . . . Thursday, August 19, 2021

Results of allocation for the Hong Kong Public Offering will be available at [www.iporeresults.com.hk](http://www.iporeresults.com.hk) (alternatively: English <https://www.eipo.com.hk/en/Allotment>; Chinese <https://www.eipo.com.hk/zh-hk/Allotment>) with a "search by ID" function . . . . . Thursday, August 19, 2021 to Wednesday, August 25, 2021

The allocation results telephone enquiry by calling +852 2862 8555 between . . . . . 9:00 a.m. to 6:00 p.m. on Thursday, August 19, 2021 to Tuesday, August 24, 2021

Dispatch/collection of Share certificates or deposit of Share certificates into CCASS in respect of wholly or partially successful applications pursuant to the Hong Kong Public Offering on or before . . . . . Thursday, August 19, 2021

Dispatch/collection of **White Form** e-Refund payment instructions/refund cheques on or before . . . . . Thursday, August 19, 2021

Dealings in H Shares on the Stock Exchange expected to commence at 9:00 a.m. on . . . . . Friday, August 20, 2021

## SETTLEMENT

Subject to the granting of the approval for listing of, and permission to deal in, the H Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the H Shares on the Stock Exchange or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second business day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the H Shares to be admitted into CCASS. Investors should seek the advice of their stockbrokers or other professional advisers for details of the settlement arrangement as such arrangements may affect their rights and interests.

## ELECTRONIC APPLICATION CHANNELS

### White Form eIPO

You may submit your application to the designated **White Form eIPO** Service Provider at [www.eipo.com.hk](http://www.eipo.com.hk) (24 hours daily, except on the last application day) from 9:00 a.m. on Tuesday, August 10, 2021 until 11:30 a.m. on Friday, August 13, 2021 and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Friday, August 13, 2021 or such later time under the section headed “How to Apply for Hong Kong Offer Shares – 11. Effect of Bad Weather on the Opening and Closing of the Application Lists” in the Prospectus.

### CCASS EIPO

CCASS Clearing/Custodian Participants can input **electronic application instructions** at the following times on the following dates:<sup>(1)</sup>

Tuesday, August 10, 2021	–	9:00 a.m. to 8:30 p.m.
Wednesday, August 11, 2021	–	8:00 a.m. to 8:30 p.m.
Thursday, August 12, 2021	–	8:00 a.m. to 8:30 p.m.
Friday, August 13, 2021	–	8:00 a.m. to 12:00 noon

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Tuesday, August 10, 2021 until 12:00 noon on Friday, August 13, 2021 (24 hours daily, except on Friday, August 13, 2021, the last application day).

The latest time for inputting your **electronic application instructions** will be 12:00 noon on Friday, August 13, 2021, the last day for applications, or such later time as described in the section headed “How to Apply for Hong Kong Offer Shares – 11. Effect of Bad Weather on the Opening and Closing of the Application Lists” in the Prospectus.

*Note:*

(1) These times are subject to change as HKSCC may determine from time to time with prior notification to CCASS.

The application monies (including the brokerage fees, SFC transaction levy and the Stock Exchange trading fee) will be held by the receiving bank and on behalf of the Company after the closing of the application lists and the refund monies, if any, will be returned to the applicants without interest on or before Thursday, August 19, 2021.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” of the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

**Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the Green Application Form and the designated website ([www.eipo.com.hk](http://www.eipo.com.hk)) for White Form eIPO.**

## **PUBLICATION OF RESULTS**

The Company expects to announce the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on Thursday, August 19, 2021 on the Company’s website at [www.strokemedical.com](http://www.strokemedical.com) and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be available through a variety of channels at the times and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares – 12. Publication of Results” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the Offer Price as finally determined is less than the maximum Offer Price of HK\$171.00 per Offer Share (excluding brokerage, SFC transaction levy and the Stock Exchange trading fee thereon), or if the conditions of the Hong Kong Public Offering are not fulfilled in accordance with “Structure of the Global Offering – Conditions of the Hong Kong Public Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy and the Stock Exchange trading fee, will be refunded, without interest or the cheque or banker’s cashier order will not be cleared.

No temporary documents of title will be issued in respect of the H Shares and no receipt will be issued for sums paid on application. H Share certificates will only become valid at 8:00 a.m. on Friday, August 20, 2021, provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus has not been exercised.

Assuming the Global Offering becomes unconditional at or before 8:00 a.m. on Friday, August 20, 2021, dealings in the H Shares are expected to commence at 9:00 a.m. on Friday, August 20, 2021. The H Shares will be traded in board lots of 50 H Shares each. The stock code of the H Shares is 6609.

*This announcement is available for viewing on the website of the Company at [www.strokemedical.com](http://www.strokemedical.com) and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).*

By order of the Board  
**Shanghai HeartCare Medical Technology Corporation Limited**  
**Mr. Wang Guohui**  
*Chairman*

Hong Kong, August 10, 2021

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. WANG Guohui as Chairman and executive Director, Ms. ZHANG Kun as an executive Director, Mr. DING Kui, Mr. LIU Yanbin, Mr. CHEN Gang, Mr. OUYANG Xiangyu as non-executive Directors, and Mr. GUO Shaomu, Mr. FENG Xiangqian and Mr. GONG Ping as independent non-executive Directors.*